CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
43.67
0.92%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.17
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Rhythm Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 43.27
Open* 42.54
1-Year Change* 74.92%
Day's Range* 42.54 - 45.19
52 wk Range 15.50-50.28
Average Volume (10 days) 856.61K
Average Volume (3 months) 15.11M
Market Cap 2.42B
P/E Ratio -100.00K
Shares Outstanding 59.10M
Revenue 61.98M
EPS -3.26
Dividend (Yield %) N/A
Beta 1.95
Next Earnings Date Feb 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 43.67 1.08 2.54% 42.59 45.35 42.54
Feb 29, 2024 43.27 -2.17 -4.78% 45.44 45.64 42.56
Feb 28, 2024 44.24 0.04 0.09% 44.20 45.32 43.74
Feb 27, 2024 45.96 -0.44 -0.95% 46.40 47.09 45.84
Feb 26, 2024 46.00 1.80 4.07% 44.20 46.69 44.20
Feb 23, 2024 45.04 1.10 2.50% 43.94 45.57 43.69
Feb 22, 2024 43.98 -4.81 -9.86% 48.79 48.79 43.44
Feb 21, 2024 48.77 0.33 0.68% 48.44 48.85 47.04
Feb 20, 2024 49.03 1.09 2.27% 47.94 49.59 47.94
Feb 16, 2024 49.10 -0.32 -0.65% 49.42 49.92 48.45
Feb 15, 2024 50.33 0.33 0.66% 50.00 51.64 49.18
Feb 14, 2024 49.91 0.83 1.69% 49.08 50.45 48.14
Feb 13, 2024 48.83 -1.00 -2.01% 49.83 49.92 44.72
Feb 12, 2024 52.38 1.64 3.23% 50.74 52.45 50.16
Feb 9, 2024 51.07 3.15 6.57% 47.92 51.58 46.94
Feb 8, 2024 47.49 0.05 0.11% 47.44 48.44 46.34
Feb 7, 2024 47.64 -0.23 -0.48% 47.87 48.36 45.21
Feb 6, 2024 47.57 2.13 4.69% 45.44 48.59 45.32
Feb 5, 2024 45.89 1.80 4.08% 44.09 46.16 43.36
Feb 2, 2024 44.79 0.35 0.79% 44.44 45.47 44.28

Rhythm Pharma Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

19:50

Country

US

Event

Rhythm Pharmaceuticals Inc at TD Cowen Health Care Conference
Rhythm Pharmaceuticals Inc at TD Cowen Health Care Conference

Forecast

-

Previous

-
Tuesday, April 30, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Rhythm Pharmaceuticals Inc Earnings Release
Q1 2024 Rhythm Pharmaceuticals Inc Earnings Release

Forecast

-

Previous

-
Thursday, June 20, 2024

Time (UTC)

18:00

Country

US

Event

Rhythm Pharmaceuticals Inc Annual Shareholders Meeting
Rhythm Pharmaceuticals Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 23.638 3.154 0 0 0
Total Operating Expense 202.795 173.213 136.575 146 78.417
Selling/General/Admin. Expenses, Total 92.032 68.486 46.125 36.55 28.08
Research & Development 108.63 104.128 90.45 109.45 50.337
Operating Income -179.157 -170.059 -136.575 -146 -78.417
Interest Income (Expense), Net Non-Operating -1.172 0.447 2.579 5.271 4.353
Other, Net -0.79 100 0 0
Net Income Before Taxes -181.119 -69.612 -133.996 -140.729 -74.064
Net Income After Taxes -181.119 -69.612 -133.996 -140.729 -74.064
Net Income Before Extra. Items -181.119 -69.612 -133.996 -140.729 -74.064
Net Income -181.119 -69.612 -133.996 -140.729 -74.064
Total Adjustments to Net Income 0 0
Income Available to Common Excl. Extra. Items -181.119 -69.612 -133.996 -140.729 -74.064
Income Available to Common Incl. Extra. Items -181.119 -69.612 -133.996 -140.729 -74.064
Diluted Net Income -181.119 -69.612 -133.996 -140.729 -74.064
Diluted Weighted Average Shares 52.1207 49.6003 44.1272 36.4225 31.004
Diluted EPS Excluding Extraordinary Items -3.47499 -1.40346 -3.03658 -3.8638 -2.38885
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -3.47499 -1.40346 -3.03658 -3.8638 -2.38885
Revenue 23.638 3.154
Cost of Revenue, Total 2.133 0.599
Gross Profit 21.505 2.555
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 19.221 11.469 8.79 4.284 9.066
Revenue 19.221 11.469 8.79 4.284 9.066
Cost of Revenue, Total 2.236 1.421 1.028 0.497 0.378
Gross Profit 16.985 10.048 7.762 3.787 8.688
Total Operating Expense 65.825 64 50.893 43.551 54.162
Selling/General/Admin. Expenses, Total 30.046 24.634 26.317 21.938 22.328
Research & Development 33.543 37.945 23.548 21.116 31.456
Operating Income -46.604 -52.531 -42.103 -39.267 -45.096
Interest Income (Expense), Net Non-Operating -0.082 0.379 0.03 -1.224 0.095
Other, Net -0.017 -0.027 -0.42 -0.37 0
Net Income Before Taxes -46.703 -52.179 -42.493 -40.861 -45.001
Net Income After Taxes -46.703 -52.179 -42.493 -40.861 -45.001
Net Income Before Extra. Items -46.703 -52.179 -42.493 -40.861 -45.001
Net Income -46.703 -52.179 -42.493 -40.861 -45.001
Income Available to Common Excl. Extra. Items -46.703 -52.179 -42.493 -40.861 -45.001
Income Available to Common Incl. Extra. Items -46.703 -52.179 -42.493 -40.861 -45.001
Diluted Net Income -46.703 -52.179 -42.493 -40.861 -45.001
Diluted Weighted Average Shares 56.8677 56.709 56.3455 51.4009 50.398
Diluted EPS Excluding Extraordinary Items -0.82126 -0.92012 -0.75415 -0.79495 -0.89291
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.82126 -0.92012 -0.75415 -0.79495 -0.89291
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 354.236 308.387 181.668 302.404 258.689
Cash and Short Term Investments 333.288 294.855 172.792 292.459 252.061
Cash & Equivalents 127.677 59.248 100.854 62.294 49.542
Short Term Investments 205.611 235.607 71.938 230.165 202.519
Prepaid Expenses 4.392 8.404 5.828 6.438 5.288
Other Current Assets, Total 7.415 4.103 3.048 3.507 1.34
Total Assets 382.481 329.523 187.073 308.523 260.21
Property/Plant/Equipment, Total - Net 3.379 4.335 5.002 5.716 1.12
Property/Plant/Equipment, Total - Gross 6.534 6.593 6.444 6.468 1.929
Accumulated Depreciation, Total -3.155 -2.258 -1.442 -0.752 -0.809
Note Receivable - Long Term
Other Long Term Assets, Total 16.983 12.143 0.403 0.403 0.401
Total Current Liabilities 39.809 43.427 17.994 24.417 13.582
Accounts Payable 4.797 5.737 4.9 10.415 7.64
Accrued Expenses 33.578 30.69 13.094 14.002 5.942
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.434 7 0
Total Liabilities 118.219 45.372 20.545 27.503 13.954
Total Long Term Debt 75.81 0 0 0 0.372
Other Liabilities, Total 2.6 1.945 2.551 3.086
Total Equity 264.262 284.151 166.528 281.02 246.256
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.056 0.05 0.044 0.044 0.034
Additional Paid-In Capital 974.356 813.041 625.762 606.307 430.824
Retained Earnings (Accumulated Deficit) -710.058 -528.939 -459.327 -325.331 -184.602
Total Liabilities & Shareholders’ Equity 382.481 329.523 187.073 308.523 260.21
Total Common Shares Outstanding 56.6124 50.2836 44.2359 43.9967 34.4107
Long Term Debt 75.81 0 0.372
Other Equity, Total -0.092 -0.001 0.049
Total Receivables, Net 6.224 1.025
Accounts Receivable - Trade, Net 6.224 1.025
Intangibles, Net 7.883 4.658
Total Inventory 2.917
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 329.201 283.878 317.838 354.236 361.874
Cash and Short Term Investments 299.26 253.602 294.582 333.288 347.795
Cash & Equivalents 64.593 115.684 109.661 127.677 185.087
Short Term Investments 234.667 137.918 184.921 205.611 162.708
Prepaid Expenses 7.638 10.267 9.652 4.392 10.751
Total Assets 354.199 309.943 345.678 382.481 389.614
Property/Plant/Equipment, Total - Net 2.433 2.763 3.089 3.379 3.699
Intangibles, Net 7.242 7.456 7.669 7.883 8.097
Other Long Term Assets, Total 15.323 15.846 17.082 16.983 15.944
Total Current Liabilities 50.144 46.103 46.029 39.809 33.098
Accounts Payable 3.839 8.383 13.347 4.797 4.933
Accrued Expenses 36.569 30.385 26.989 33.578 26.405
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 156.725 127.658 125.915 118.219 108.419
Total Long Term Debt 104.699 79.347 77.52 75.81 72.961
Deferred Income Tax
Other Liabilities, Total 1.882 2.208 2.366 2.6 2.36
Total Equity 197.474 182.285 219.763 264.262 281.195
Common Stock 0.059 0.057 0.056 0.056 0.056
Additional Paid-In Capital 1050.63 991.182 981.95 974.356 949.043
Retained Earnings (Accumulated Deficit) -853.103 -808.94 -762.237 -710.058 -667.565
Other Equity, Total -0.113 -0.014 -0.006 -0.092 -0.339
Total Liabilities & Shareholders’ Equity 354.199 309.943 345.678 382.481 389.614
Total Common Shares Outstanding 59.0894 56.8961 56.8524 56.6124 55.7563
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Total Receivables, Net 14.541 13.831 8.117 6.224 3.328
Accounts Receivable - Trade, Net 14.541 13.831 8.117 6.224 3.328
Other Current Assets, Total 7.415
Property/Plant/Equipment, Total - Gross 6.534
Accumulated Depreciation, Total -3.155
Other Current Liabilities, Total 9.736 7.335 5.693 1.434 1.76
Long Term Debt 104.699 79.347 77.52 75.81 72.961
Total Inventory 7.762 6.178 5.487 2.917
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -181.119 -69.612 -133.996 -140.729 -74.064
Cash From Operating Activities -173.428 -146.003 -121.98 -122.75 -62.056
Cash From Operating Activities 1.672 1.158 0.69 0.834 0.442
Non-Cash Items 25.743 -79.446 17.221 12.078 10.899
Changes in Working Capital -19.724 1.897 -5.895 5.067 0.667
Cash From Investing Activities 28.029 -62.159 158.531 -27.97 -87.148
Capital Expenditures -0.281 -0.434 -0.214 -3.385 -0.722
Other Investing Cash Flow Items, Total 28.31 -61.725 158.745 -24.585 -86.426
Cash From Financing Activities 213.828 166.481 2.009 163.474 164.686
Issuance (Retirement) of Stock, Net 141.49 166.481 2.009 163.474 164.686
Net Change in Cash 68.429 -41.681 38.56 12.754 15.482
Issuance (Retirement) of Debt, Net 72.338
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -52.179 -181.119 -138.626 -97.765 -52.764
Cash From Operating Activities -36.433 -173.428 -139.428 -92.441 -53.632
Cash From Operating Activities 0.457 1.672 1.23 0.788 0.35
Deferred Taxes 0 0 0
Non-Cash Items 14.876 25.743 17.576 9.664 4.546
Changes in Working Capital 0.413 -19.724 -19.608 -5.128 -5.764
Cash From Investing Activities 18.464 28.029 68.804 108.501 72.522
Capital Expenditures -0.047 -0.281 -0.282 -0.187 -0.127
Other Investing Cash Flow Items, Total 18.511 28.31 69.086 108.688 72.649
Cash From Financing Activities -0.133 213.828 196.463 37.899 0.399
Issuance (Retirement) of Stock, Net 1.218 141.49 121.463 0.399 0.399
Net Change in Cash -18.016 68.429 125.839 53.959 19.289
Issuance (Retirement) of Debt, Net -1.351 72.338 75 37.5
Foreign Exchange Effects 0.086
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
PRIMECAP Management Company Investment Advisor 14.5854 8299317 692006 2023-06-30
Baker Bros. Advisors LP Hedge Fund 11.4202 6498267 0 2023-06-30 LOW
RA Capital Management, LP Hedge Fund 9.9752 5676067 160000 2023-06-30 LOW
Goldman Sachs & Company, Inc. Research Firm 8.9977 5119805 -168565 2023-06-30 MED
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.184 3518783 2246151 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.7422 3267425 655237 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.1343 2921508 281293 2023-06-30 LOW
New Enterprise Associates (NEA) Venture Capital 5.114 2909956 0 2023-06-30 LOW
Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 4.1147 2341335 -1550348 2023-08-31 LOW
Polar Capital LLP Investment Advisor/Hedge Fund 3.9542 2250000 500000 2023-06-30 LOW
Frazier Healthcare Partners Venture Capital 3.8087 2167222 2483 2023-06-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 3.0276 1722723 131177 2023-06-30 LOW
Rock Springs Capital Management LP Hedge Fund 2.8068 1597123 0 2023-06-30 LOW
Alkeon Capital Management LLC Investment Advisor/Hedge Fund 2.5322 1440834 -249008 2023-06-30 LOW
VR Adviser, LLC Venture Capital 1.9156 1090000 1090000 2023-06-30 MED
Janus Henderson Investors Investment Advisor/Hedge Fund 1.8949 1078207 -19366 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.7106 973350 500589 2023-06-30 LOW
Medical Strategy GmbH Investment Advisor 1.5604 887895 125000 2023-05-31 MED
Braidwell LP Hedge Fund 1.4817 843087 843087 2023-06-30 HIGH
Great Point Partners, LLC Hedge Fund 1.3567 772000 674456 2023-06-30 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Rhythm Pharma Company profile

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). Its lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. It is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. It targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Rhythm Pharmaceuticals Inc revenues increased from $0K to $3.2M. Net loss decreased 48% to $69.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$3.04 to -$1.40.

Industry: Bio Therapeutic Drugs

222 Berkeley Street
12th Floor Boston
BOSTON
MASSACHUSETTS 02116
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

BTC/USD

61,971.75 Price
-1.090% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

XRP/USD

0.64 Price
+5.550% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

79.49 Price
+1.850% 1D Chg, %
Long position overnight fee 0.0266%
Short position overnight fee -0.0485%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

18,286.90 Price
+1.410% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading